Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIa clinical study of NB1111 in USA

Trial Profile

A phase IIa clinical study of NB1111 in USA

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tetrahydrocannabinol valine hemisuccinate (Primary)
  • Indications Glaucoma; Ocular hypertension
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jul 2023 According to a Skye Bioscience media release, the contract manufacturer, NextPharma Oy, in Finland, has completed production of placebo and SBI-100 Ophthalmic Emulsion for this study. Skye is completing additional logistical and preparatory steps necessary to start this study. The company expects to start enrolling study in 3Q 2023.
    • 19 Aug 2022 According to a Skye Bioscience media release, the company expects to complete enrollment in early 2023 and to release interim data from that study in Q2 2023.
    • 19 Aug 2022 According to a Skye Bioscience media release, the company has regulatory approval to start this study and the company expects its contract manufacturer to start manufacturing placebo and SBI-100 for this study to establish the safety and tolerability of SBI-100 in early September.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top